1. Mesa RA, Shields A, Hare T, et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res. 2013;37:911–6.
2. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109:68–76.
3. European Medicines Agency. Reflection paper on the use of patient reported outcome (PRO) measures in oncology studies (draft). 2014.
https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-patient-reported-outcome-pro-measures-oncology-studies_en.pdf
. Accessed 26 Mar 2019.
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Et al: Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims, 2009.
5. Incyte. FDA Approves Incyte's Jakafi (TM) (ruxolitinib) for Patients with Myelofibrosis. 2011.
https://investor.incyte.com/news-releases/news-release-details/fda-approves-incytes-jakafitm-ruxolitinib-patients-myelofibrosis
. Accessed 26 Mar 2019.